PD-L1 antibody (AA 13-224)
Quick Overview for PD-L1 antibody (AA 13-224) (ABIN5027497)
Target
See all PD-L1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 13-224
-
Purification
- Protein G Chromatography
-
Immunogen
- A partial length recombinant protein of PD-L1 (amino acid 13-224) was used as the immunogen for this antibody.
-
Isotype
- IgG2b kappa
-
-
-
-
Application Notes
- FACS: 0.5-1 μg/10^6 cells, WB: 2-4 μg/mL, IHC: 5-10 μg/mL
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 0.5 mg/mL
-
Buffer
- PBS containing 0.05 % BSA, PH 7.4
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.
-
-
-
: "Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin." in: PLoS ONE, Vol. 16, Issue 1, pp. e0245581, (2021) (PubMed).
-
-
- PD-L1 (CD274 (PD-L1))
-
Alternative Name
- PDL-1
-
Background
- PD-L1 (CD274/B7-H1) is a critical membrane-bound costimulatory molecule belongs to the B7 superfamily that inhibits immune responses through its receptor, PD-1 and PD-L1 play a key role in the pathogenesis of inflammatory diseases (programmed death 1). It is widely expressed in the mononuclear phagocyte system (MPS), may co-stimulate T cells and regulates inflammatory responses. PD-L1 exerts inflammation regulatory functions via a negative co-stimulatory effect on T cell functions to inhibit cytokine secretion, facilitate apoptosis of activated T cells and induce T cell anergy. Aberrant expression and dysregulation of CD274 have been reported during bacterial infection, inflammation and in numerous autoimmune diseases.
-
Molecular Weight
- 44 kDa
-
Gene ID
- 29126
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-